An interval of fewer than 30 days between the last immunotherapy dose and the liver transplant increases the rejection risk ...

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...

The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...

Liver cancer often remains undetected until advanced stages. Learn about the causes and how you can protect yourself with ...

Discover the 7 major risk factors for liver cancer, from viral hepatitis to genetics. Learn how lifestyle changes and early ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...

SaveHealth provides an overview of the different illnesses that typically come on with age, as well as treatment and ...

Liver cancer in the Philippines holds a staggering mortality rate of 11.6 out of 100,000 individuals, compared to the global death rate of 7.8/100,000. This reflects the significant impact of liver ...

Liver cancer is the fourth most common cancer and the fourth leading cause of cancer-related deaths in the country.

Treatment with thermal ablation was noninferior to surgical resection in small-size colorectal liver metastases, according to ...

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...

Opens in a new tab or window PET-CT imaging with [18 F]fluorodeoxyglucose (FDG) and [18 F]fluorocholine (FCH) altered treatment plans ... as Barcelona Clinical Liver Cancer (BCLC) tumor stage ...